表紙
市場調查報告書
商品編碼
1029284

降血脂藥物的全球市場:產業趨勢,市場佔有率,市場規模,成長,機會,預測(2021年∼2026年)

Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 141 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球降血脂藥物市場規模,從2021年到2026年,預計穩定成長。

全球的高血脂症增加,是促進市場成長的重要要素之一。再加上高等級的膽固醇和容易受心血管疾病影響的老年人口增加,也成為市場成長的原動力。還有國民的健康意識高漲,及高膽固醇症的治療方法相關意識的高漲,也推動市場成長。

提高有效性的新藥物的開發等,各種技術的進步也成為促進市場成長的要素。其他因素,如生物醫學領域的廣泛研究開發活動,及全球性醫療基礎設施的改善等,更加推動市場。

本報告提供全球降血脂藥物市場的相關調查,市場概要,市場分析,價格分析,競爭情形,企業簡介等全面性資訊。

目錄

第1章 序文

第2章 範圍及調查手法

第3章 摘要整理

第4章 簡介

第5章 全球降血脂藥物市場

  • 市場概要
  • 市場效能
  • COVID-19的影響

第6章 市場明細:各藥物類型

  • Statin
  • 膽汁酸封鎖劑
  • 膽固醇吸收抑制劑
  • PCSK9抑制劑
  • 其他

第7章 市場明細:各終端用戶

  • 醫院
  • 診所
  • 其他

第8章 市場明細:各地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 其他
  • 中東及非洲
    • 市場明細:各國

第9章 SWOT分析

第10章 價值鏈分析

第11章 波特的五力分析

第12章 價格分析

第13章 競爭情形

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Amgen Inc.
    • AstraZeneca Plc
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • Esperion Therapeutics Inc.
    • GlaxoSmithKline Pharmaceuticals Limited(GlaxoSmithKline Plc)
    • Immuron Limited
    • Ionis Pharmaceuticals Inc.
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi S.A.
目錄
Product Code: SR1020F234_Report

The global hyperlipidemia drugs market is expected to exhibit stable growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by high levels of fats in the bloodstream. It is the abnormal elevation of lipids and/or lipoprotein levels that can lead to stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic factors, unhealthy lifestyles and inadequate diet. Some of the commonly used hyperlipidemia drugs include statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates and combination and miscellaneous antihyperlipidemic agents. These drugs reduce cholesterol production levels in the liver while further removing it from the bloodstream.

The increasing prevalence of hyperlipidemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to high levels of cholesterol and cardiovascular diseases, is also driving the market growth. In line with this, rising health consciousness among the masses and growing awareness regarding the available treatment alternatives for hypercholesterolemia is also favoring the market growth. Additionally, various technological advancements, such as the development of novel drug classes with enhanced efficacy, are acting as other growth-inducing factors. These drugs offer improved endothelial function and stability of atherosclerotic plaques and cause minimal inflammation and damage to the cells. Other factors, including the extensive research and development (R&D) activities in the field of biomedical sciences, along with overall improvements in the healthcare infrastructure across the globe, are anticipated to drive the market further.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global hyperlipidemia drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on drug type and end-user.

Breakup by Drug Type:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • PCSK9 Inhibitors
  • Others

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A. Key Questions Answered in This Report:

  • How has the global hyperlipidemia drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hyperlipidemia drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hyperlipidemia drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hyperlipidemia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 PCSK9 Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Daiichi Sankyo Company Limited
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Eli Lilly and Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Esperion Therapeutics Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Immuron Limited
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Ionis Pharmaceuticals Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hyperlipidemia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Hyperlipidemia Drugs Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Hyperlipidemia Drugs Market: Breakup by Drug Type (in %), 2020
  • Figure 4: Global: Hyperlipidemia Drugs Market: Breakup by End User (in %), 2020
  • Figure 5: Global: Hyperlipidemia Drugs Market: Breakup by Region (in %), 2020
  • Figure 6: Global: Hyperlipidemia Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 7: Global: Hyperlipidemia Drugs (Statins) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 8: Global: Hyperlipidemia Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 9: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Hyperlipidemia Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Hyperlipidemia Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Hyperlipidemia Drugs (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Hyperlipidemia Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: Hyperlipidemia Drugs (Clinics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: Hyperlipidemia Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: Global: Hyperlipidemia Drugs (Other End Users) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: Global: Hyperlipidemia Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: North America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: North America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: United States: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: United States: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: Canada: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: Canada: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Asia Pacific: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Asia Pacific: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: China: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: China: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: Japan: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: Japan: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: India: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: India: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: South Korea: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: South Korea: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: Australia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: Australia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: Indonesia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: Indonesia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: Europe: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: Europe: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: Germany: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: Germany: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: France: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: France: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: United Kingdom: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: United Kingdom: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: Italy: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: Italy: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Spain: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Spain: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: Russia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: Russia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: Latin America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: Latin America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: Brazil: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: Brazil: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: Mexico: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: Mexico: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 68: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 69: Middle East and Africa: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 70: Middle East and Africa: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 71: Global: Hyperlipidemia Drugs Industry: SWOT Analysis
  • Figure 72: Global: Hyperlipidemia Drugs Industry: Value Chain Analysis
  • Figure 73: Global: Hyperlipidemia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hyperlipidemia Drugs Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
  • Table 3: Global: Hyperlipidemia Drugs Market Forecast: Breakup by End User (in Million US$), 2021-2026
  • Table 4: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 5: Global: Hyperlipidemia Drugs Market Structure
  • Table 6: Global: Hyperlipidemia Drugs Market: Key Players